Home › Funds › SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC › ASND

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC position in ASND

ASCENDIS PHARMA A/S · Health Care

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reported holding 110,000 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$25.1M, representing 0.75% of its reported portfolio and ranking #42 among its reported holdings. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed ASND holdings in 8 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)110.00K sh
Reported value held$25.06M
Portfolio Weight0.75%
First reportedQ1 2024
Last changeNew
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's ASND position evolved

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC first disclosed a stake in ASND in Q1 2024 at 75,100 shares (US$11.4M). The position peaked in Q3 2026 at 110,000 shares, worth US$25.1M. Across 8 filings, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 110,000 shares valued at US$25.1M. Notable position changes include a 74% increase in Q2 2024 (shares rose 9% over the following quarter), a 58% trim in Q3 2024 (shares fell 8% over the following quarter), a 435% increase in Q2 2025 (shares rose 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 75.10K $11.35M New
Q2 2024 130.70K $17.82M Add
Q3 2024 55.10K $8.23M Reduce
Q4 2024 24.60K $3.39M Reduce
Q1 2025 24.30K $3.79M Reduce
Q2 2025 130.00K $22.44M Add
Q3 2025 100.00K $19.88M Reduce
Q3 2026 110.00K $25.06M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 36 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.17B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC held ASND?

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed ASND holdings in 8 of the last 11 reported quarters, going back to Q1 2024.

What is SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's current position in ASND?

As of Q3 2026, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds 110.00K shares of ASND (ASCENDIS PHARMA A/S), valued at $25.06M, representing 0.75% of its reported portfolio and ranking #42.

Has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC been buying or selling ASND?

In the latest 13F filing (Q3 2026), SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC newly opened its position in ASND. The position peaked in Q3 2026 at 110.00K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., WESTFIELD CAPITAL MANAGEMENT CO LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.